This leads to the conclusion, that inhibition of muscle PFK-1 could improve physiological processes and support the treatment of obesity, diabetes and metabolic syndrome (Malina et al., 2014). Here, PFKM is linked to obesity due to melanocortin 4 receptor deficiency.